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Summary
Background The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation 
with cells that did not express CCR5 (CCR5Δ32/Δ32); remission was reported at 18 months after analytical treatment 
interruption (ATI). Here, we present longer term data for this patient (up to 30 months after ATI), including sampling 
from diverse HIV-1 reservoir sites. 
Methods We used ultrasensitive viral load assays of plasma, semen, and cerebrospinal fluid (CSF) samples to detect 
HIV-1 RNA. In gut biopsy samples and lymph-node tissue, cell-copy number and total HIV-1 DNA levels were 
quantified in multiple replicates, using droplet digital PCR (ddPCR) and quantitative real-time PCR. We also analysed 
the presence of intact proviral DNA using multiplex ddPCR targeting the packaging signal (ψ) and envelope (env). 
We did intracellular cytokine staining to measure HIV-1-specific T-cell responses. We used low-sensitive and 
low-avidity antibody assays to measure the humoral response to HIV-1. We predicted the probability of rebound using 
a mathematical model and inference approach.
Findings HIV-1 viral load in plasma remained undetectable in the London patient up to 30 months (last tested on 
March 4, 2020), using an assay with a detection limit of 1 copy per mL. The patient’s CD4 count was 430 cells per µL 
(23·5% of total T cells) at 28 months. A very low-level positive signal for HIV-1 DNA was recorded in peripheral 
CD4 memory cells at 28 months. The viral load in semen was undetectable in both plasma (lower limit of detection 
[LLD] <12 copies per mL) and cells (LLD 10 copies per 10⁶ cells) at 21 months. CSF was within normal parameters 
at 25 months, with HIV-1 RNA below the detection limit (LLD 1 copy per mL). HIV-1 DNA by ddPCR was negative 
in rectum, caecum, and sigmoid colon and terminal ileum tissue samples at 22 months. Lymph-node tissue from 
axilla was positive for the long-terminal repeat (33 copies per 10⁶ cells) and env (26·1 copies per 10⁶ cells), negative 
for ψ and integrase, and negative by the intact proviral DNA assay, at 27 months. HIV-1-specific CD4 and CD8 T-cell 
responses have remained absent at 27 months. Low-avidity Env antibodies have continued to decline. Mathematical 
modelling suggests that the probability of remission for life (cure) is 98% in the context of 80% donor chimerism 
in total HIV target cells and greater than 99% probability of remission for life with 90% donor chimerism.
Interpretation The London patient has been in HIV-1 remission for 30 months with no detectable replication-competent virus 
in blood, CSF, intestinal tissue, or lymphoid tissue. Donor chimerism has been maintained at 99% in peripheral T cells. 
We propose that these findings represent HIV-1 cure.
Funding Wellcome Trust and amfAR (American Foundation for AIDS Research).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
HIV cure, exemplified by extended periods off 
antiretroviral therapy (ART) with negative results on 
testing for HIV nucleic acid and loss of adaptive 
immune responses, has been elusive. For a decade, only 
one such case, referred to as the Berlin patient, was 
recognised.1–3 This individual underwent two rounds of 
total body irradiation and allogeneic haemopoietic stem-
cell transplantation (allo-HSCT) with donor cells that 
did not express CCR5 (CCR5Δ32/Δ32) for treatment of 
acute myelogenous leukaemia. In 2019 we reported 
HIV-1 remission in the London patient (participant 36 
in the IciStem cohort [IciS-36]),4 who underwent one 
HSCT procedure with CCR5Δ32/Δ32 donor cells for 
treatment of refractory Hodgkin lymphoma (stage IVb). 
Remission in the London patient, shown by testing 
of plasma and circulating peripheral CD4 T cells for 
traces of HIV-1, was reported 18 months after analytical 
treatment interruption (ATI) of ART. Here, we present 
longer term clinical, laboratory, and mathematical 
modelling data to make the case for long-term remission 
of HIV-1 (cure) in this individual.
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All testing was done at University College Hospitals NHS 
Trust (London, UK). We used standard clinically validated 
hospital laboratory assays to measure HIV-1 viral load in 
plasma and semen samples. Further, we used an in-house 
ultrasensitive plasma and cerebrospinal fluid (CSF) viral 
load assay to detect HIV-1 RNA. Seminal plasma was 
separated from the cellular fraction by centrifugation. 
We centrifuged 8 mL plasma or CSF at 21 000 g for 2 h at 
4°C before removing the supernatant and resuspending 
the pellet in 700 µL of residual plasma. We then tested the 
suspension using the Hologic Aptima HIV-1 Quant Dx 
assay (Marlborough, MA, USA). We measured whole 
leucocyte and T-cell-specific (CD3-selected) chimerism by 
short tandem repeat analysis with the PowerPlex16 
system (Promega, Madison, WI, USA).
Blood and tissue processing
We isolated peripheral blood mononuclear cells (PBMCs) 
from 60 mL EDTA (edetic acid) blood by centrifugation 
on a Ficoll gradient, and did magnetic activated cell 
sorting to retrieve naive T cells and memory T cells (CD4+ 
T-Cell and Tnaïve CD4+ Cell Isolation Kit; Miltenyi Biotec, 
Cologne, Germany). DNA was isolated using a DNeasy 
Blood and Tissue kit (Qiagen, Hilden, Germany). Biopsy 
samples of gut tissue (rectum, caecum, and sigmoid 
colon and terminal ileum) were obtained by colonoscopy 
and homogenised using ceramic beads in a MagNA 
Lyser (Roche, Basel, Switzerland) set at 6000 rpm for 
45 s, as described.5 DNA was extracted using an Qiagen 
AllPrep DNA/RNA Mini kit. Increased uptake of 
¹⁸F-fluoro deoxyglucose in an axillary lymph node was 
seen on PET-CT and a diagnostic lymph-node biopsy 
sample was taken. The biopsy specimen was processed 
the same way as were the gut biopsy samples.
Quantitative real-time PCR
For each quantitative real-time PCR (rtPCR), standards 
were tested in triplicate, in addition to two positive 
control wells in triplicate and six negative control wells. 
We used 25 000 cells’ worth of DNA (based on albumin 
rtPCR) per well for the London patient. The packaging 
site (ψ) rtPCR amplifies a fragment between positions 
692 and 797. The envelope (env) PCR amplifies a fragment 
between positions 7736 and 7851.
Droplet digital PCR
We quantified HIV-1 DNA using droplet digital PCR 
(ddPCR; Bio-Rad, Hercules, CA, USA) targeting the 
long terminal repeat (LTR), gag, and integrase regions, 
shown as target copies per 10⁶ cells tested.6 We measured 
in duplicate amounts of the human gene for 
RNase P (RPP30), which is present twice in diploid 
cells, to ascertain the input cell number. In all ddPCR 
runs, water and donor PBMCs were tested in duplicate 
as negative controls for HIV target regions and U1 cells 
were tested as a positive control. Samples generating 
one positive droplet were interpreted as negative based 
on the occurrence of a sporadic positive droplet in the 
negative controls (one in 40 reactions). We further 
analysed samples showing at least two positive droplets 
in an intact proviral DNA assay (IPDA), essentially as 
des cribed.7 The IPDA assay is based on a duplex ddPCR 
targeting two regions in the viral genome that are 
present in most intact proviruses, ψ and the Rev 
response element (RRE) in env. The env ddPCR also 
contains a probe without a fluorescent label that can 
discriminate G-A hypermutated proviruses. Again, to 
ascertain cell number and DNA shearing, RPP30 was 
targeted and ddPCR controls were used. The DNA 
shearing index was calculated to correct the number of 
intact proviruses (double positives for ψ and env).
Research in context
Evidence before this study
We searched PubMed on Feb 1, 2020, with the terms “allogeneic 
transplantation”, “CCR5”, and “HIV”, and either “cure” or 
“remission”. We did not restrict our search by date or language. 
To date, the only reported case of long-term remission (cure) 
of HIV is the Berlin patient, who underwent two allogeneic 
haemopoietic stem-cell transplantation (allo-HSCT) procedures 
using cells from a homozygous CCR5Δ32 (CCR5Δ32/Δ32) donor. 
Despite reports showing unsuccessful allo-HSCT with 
CCR5Δ32/Δ32 tissue, in 2019 we reported an individual (the 
London patient) who achieved long-term suppression of HIV-1 
after such a procedure. We did not report data for HIV-1 testing 
of reservoirs other than blood.
Added value of this study
We have shown in the London patient an absence of HIV-1 
replication in samples of blood, cerebrospinal fluid, semen, 
intestinal tissue, and lymphoid tissue up to 30 months after 
analytical treatment interruption of antiretroviral therapy. 
Remnants of integrated HIV-1 DNA sequences that are unlikely 
to be capable of producing virus remain in tissue samples and 
can be regarded as so-called fossils. Antibodies to HIV-1 
envelope protein remain positive.
Implications of all the available evidence
Long-term remission of HIV-1 can be achieved using 
reduced-intensity drug regimens with one CCR5Δ32/Δ32 
allo-HSCT procedure without total body irradiation. Evidence 
of past HIV infection might persist analogous to antibody 
responses to other viral infections that have been cleared.
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HIV-1, cytomegalovirus, and Epstein-Barr virus 
specific CD4 and CD8 T-cell responses
For intracellular cytokine staining and peptide stimulation, 
PBMCs were thawed and resuspended in RPMI complete 
media. After overnight rest at 37°C and 5% carbon dioxide, 
PBMCs were stimulated for 6 h with 2 µg/mL HIV-1 Gag 
pools or cytomegalovirus (CMV) pp65 (JPT Peptide 
Technologies, Berlin, Germany) or the PepTivator Epstein-
Barr virus (EBV) consensus pool (Miltenyi Biotec) 
containing 43 peptides of between eight and 20 amino 
acids in length from the proteins LMP2A, BRLF1, BMLF1 
(EB2), BNLF1 (LMP1), BERF3 (EBNA6), BERF1 (EBNA3), 
BERF2 (EBNA4), BALF2 (DNBI), BMRF1, BZLF1, BNRF1 
(MTP), EBNA1, BLLF1 (gp350), and BARF in the presence 
of 1 µg/mL anti-CD28 and anti-CD49d CoStim antibodies 
(BD Biosciences, Cowley, UK), 2 µmol/L Monensin (BD 
Biosciences), 10 µg/mL Brefeldin A (Sigma, St Louis, MO, 
USA), and anti-CD107a APC-H7 antibody (BD Biosciences). 
After stimulation, virus-specific T cells were identified by 
intracellular cytokine staining.4 In brief, cells were surface 
stained with antibodies (CD14 BV510, CD19 BV510, CD3 
BV650, CD4 BV711, CD8 BV421; Biolegend, San Diego, 
CA, USA) in the presence of fixable Live/Dead stain 
(Invitrogen, Waltham, MA, USA). Cells were then fixed 
and permeabilised (CytoFix/CytoPerm; BD Biosciences) 
followed by intracellular cytokine staining for interferon γ 
with PE-Cyanine7, tumour necrosis factor with fluorescein 
isothiocyanate, and interleukin 2 with PercP eFluor710 
(eBioscience, Waltham, MA, USA). Stimulation with 
0·005% dimethyl sulphoxide in the presence of 
costimulatory antibodies, protein transport inhibitors, and 
CD107a was done as a negative control. Samples were 
acquired on a BD Fortessa X20 using BD FACSDiva8.0 
(BD Biosciences). Data were analysed using FlowJo 10 
(BD, Ashland, OR, USA).
HIV-1 antibody responses
Specific HIV-1 antibodies in longitudinal serum samples 
diluted one part in two parts were tested in a qualitative 
western blot assay (New Lav Blot I; Bio-Rad). Standard 
and low-sensitive versions of the Vitros anti-HIV-1 assay 
(Ortho-Clinical Diagnostics, High Wycombe, UK) and 
the limiting avidity antigen assay were measured in the 
same samples as described.6 Briefly, four recombinant 
antigens (HIV-1 Env 13, HIV-1 Env 10, HIV-1 p24, and 
HIV-2 Env AL) derived from HIV-1 core, HIV-1 Env, and 
HIV-2 Env proteins were quantified. The optimised 
version of the low-sensitive Vitros assay uses a one part in 
400 parts dilution of the HIV-positive sample. The cutoff 
was set at a signal to cut-off ratio (S/CO) of 20.6 The avidity 
assay measures the capacity of guanidine to elute low-
avidity and low-affinity antibodies after antigen–antibody 
bonds have formed. The results are reported as an avidity 
index, calculated as the ratio of the S/CO of the sample 
incubated in guanidine to the S/CO of the sample 
incubated in PBS, with 0·51 set as the cutoff.7
Mathematical modelling
The mathematical modelling analysis consisted of 
two parts. First, we used a mathematical model8 to 
simulate the expected distribution of rebound times as 
a function of reservoir size and target cell fraction (ie, 
chimerism). Second, we used this model with a 
previously developed Bayesian inference framework9,10 
to interpret the outcome of the London patient. In 
particular, we estimated the posterior probability of a 
particular number of cells remaining in the latent 
reservoir, in view of both the results of laboratory assays 
and the observation of no rebound for a specific time 
off ART, and the likelihood that the patient will have 
a rebound sometime in the future (vs lifetime remis s-
ion) as a function of both the degree of target cell 
Figure 1: Clinical course of the London patient up to 29 months after analytical treatment interruption
Upper panel shows peripheral blood CD4 count, plasma HIV-1 RNA, HIV-1 DNA, and chimerism in peripheral T cells 
over time. Lower panel shows amounts in DNA of CMV and EBV in plasma over time. Anti-CD52 was alemtuzumab. 
3TC=lamivudine. Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. cART=combination antiretroviral 
therapy. CMV=cytomegalovirus. CsA=ciclosporin. DTG=dolutegravir. EBV=Epstein-Barr virus. GvHD=graft versus 
host disease. FTC=emtricitabine. LACE=lomustine, cytarabine, cyclophosphamide, and etoposide. 
MTX=methotrexate. RAL=raltegravir. RPV=rilpivirine. TDF=tenofovir disoproxil fumarate.  
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susceptibility (CCR5Δ32/Δ32 chimerism) and the 
current time off ART without rebound (appendix pp 1–5).
Ethics and consent
The London patient was registered to the IciStem 
consortium as IciS-36. We obtained ethics approval from 
the UK National Health Service Health Research 
Authority Research Ethics Committee in April, 2017 
(reference 17/SW/0021, protocol no 16/0594). The patient 
provided full written informed consent in July, 2017. The 
patient also reviewed the final version of the updated 
Article and provided written consent to its publication.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had final responsibility for the decision to 
submit for publication.
Results
Since 2019,4 the London patient has shown somewhat 
slow CD4 reconstitution (figure 1). At 28 months after 
ATI, the CD4 count reached near pretransplant levels 
(430 cells per µL [23·5% of total T cells]), with CD4:CD8 
of 0·86 (normal range 1·5–2·5). However, no opportun-
istic infections were reported and peripheral T-cell 
chimerism was maintained at 99% (figure 1). 
HIV-1 plasma viral load was monitored up to 30 months 
after ATI, using a hospital-based assay with a lower limit 
of detection (LLD) of 20 copies per mL, and viral load was 
below the LLD (<1 copy per mL) up to 30 months after 
ATI using an ultrasensitive assay (viral load on 
March 4, 2020, <1 copy per mL). Reactivation of EBV at 
around 21 months after ATI, with peak viral load of 
35 000 copies per mL plasma, was managed conservatively 
without specific treatment and viral load fell to 
3500 copies per mL at 23 months. No clinically significant 
CMV reactivation was seen from 18 months to 28 months 
post ATI (figure 1). Of note, no further episodes of graft 
versus host disease (GvHD) were reported since gut 
GvHD at 2 months post-transplant,4 and no immuno-
suppressive drugs were taken after ATI. The London 
patient did not use ART for pre-exposure prophylaxis.
HIV-1 LTR ddPCR analyses were negative in bulk 
CD4 T cells (<2·4 LTR copies per 10⁶ cells) and in the naive 
CD4 T-cell subset (<3·5 LTR copies per 10⁶ cells) 28 months 
after ATI. In the memory subset, two positive droplets 
were detected in the LTR ddPCR in one of the eight repli-
cates. IPDA showed one droplet positive in six replicates 
for both ψ and HIV env. HIV env was also detected as one 
positive droplet in two other wells (appendix p 7). The 
DNA shearing index was 0·24. No correction for shearing 
was applied in view of the uncertainty of a false-positive 
signal with one double-positive droplet.
A semen sample was obtained from the individual at 
21 months after ATI. Semen viraemia was below the LLD 
in both seminal plasma (<12 copies per mL) and cells 
(<10 copies per 10⁶ cells). It was not possible to quantify 
the input number of cells in this assay, however.
Because of neurological symptoms, the London patient 
underwent MRI and lumbar puncture 25 months after 
ATI. CSF contained normal protein with no cells 
(<5 cells per µL) detected. HIV-1 viral load in CSF was 
negative (LLD 1 copy per mL).
Colonoscopy was done 22 months after ATI and tissue 
biopsy samples were taken. No evidence was seen of 
recurrence of gut GvHD. HIV-1 LTR and integrase 
ddPCR analyses were negative in all gut biopsy speci-
mens (sigmoid colon and ileum >0·2 million cells tested; 
caecum >0·3 million cells tested; rectum >0·15 million 
cells tested; appendix p 8). HIV-1 LTR DNA by rtPCR was 
also negative in rectum, caecum, and sigmoid colon and 
terminal ileum (appendix p 9).
The London patient had increased metabolic activity in 
an axillary lymph node on PET-CT and under went diag-
Figure 2: HIV Gag-specific and CMV-specific T-cell responses
Representative fluorescence-activated cell sorting plots showing percentage of virus-specific CD8 T cells (upper 
panel) and CD4 T cells (lower panel) identified via intracellular staining for IFNγ after stimulation with HIV Gag or 
CMV pp65 peptide pools at 1309 days after allo-HSCT. A negative control containing peripheral blood 
mononuclear cells from the London patient but without peptide mix was included (unstimulated) for each 
assay (A). Polyfunctional profile for CD8 and CD4 T-cell responses to CMV pp65 and HIV Gag peptide stimulation 
subsequent to Boolean gating. The functions are listed along the x axis with each of their respective 
combinations (B). Allo-HSCT=allogeneic haemopoietic stem-cell transplantation. CMV=cytomegalovirus. 
IFNγ=interferon γ. IL2=interleukin 2. TNFα=tumour necrosis factor α.
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nostic lymph node biopsy 27 months after ATI. Histology 
was reported as showing follicular hyperplasia with 
follicle lysis and large numbers of EBV-positive cells 
within the follicles, most likely a reactive lymph adeno-
pathy. The lymph node was positive for HIV-1 env 
(26·1 copies per 10⁶ cells) and LTR (33 copies per 10⁶ cells) 
by ddPCR, whereas the gag ddPCR was only slightly 
positive (5·1 copies per 10⁶ cells) and no integrase DNA 
could be detected (<0·9 cells per 10⁶ cells; appendix p 6). 
In line with these observations, no intact proviral DNA 
was recorded by the IPDA assay (<0·5 intact proviral 
DNA copies per 10⁶ cells). The DNA shearing index 
was 0·39. Correction for shearing could not be applied in 
the absence of double-positive droplets.
In a second assay that used rtPCR for detection of 
HIV-1 DNA in lymph-node cells, a positive low-level env 
signal was identified at around 70 copies per 10⁶ cells 
and a positive low-level signal was seen in ψ at around 
76 copies per 10⁶ cells (appendix p 9), though IPDA was 
negative. HIV-1 LTR detection by rtPCR was negative in 
all wells. Both positive controls in triplicate on two plates 
were positive and all 12 negative controls were negative. 
Sequencing using HIV-1 env specific primers was 
unsuccessful.
The London patient had previously shown immune 
responses against CMV, but not HIV-1, up to the 18-month 
timepoint.4 We measured CD8 and CD4 T-cell virus-
specific responses after stimulation with HIV-1 Gag and 
CMV pp65 overlapping peptide pools. At 27 months after 
ATI, no interferon γ responses or polyfunctional responses 
were noted to HIV-1 Gag in CD4 and CD8 cells (figure 2). 
By contrast, CMV pp65 reactivity in CD4 and CD8 T cells 
was detected. In view of the lymph node histological 
findings showing B-cell proliferation, we wondered 
whether EBV reactivation could have triggered EBV-specific 
CD4 and CD8 T-cell responses and prolif er ation, potentially 
including CD4 T cells containing HIV-1 DNA. Therefore, 
we measured EBV-specific CD8 and CD4 T-cell responses 
in peripheral blood. CD8 responses were robust and 
smaller CD4 responses were also observed (figure 3).
Antibodies against HIV-1 core and Env proteins 
measured by standard ELISA persisted within the same 
values more than 2 years after ATI. However, the low-
sensitive Vitros analysis and antibody avidity assay 
showed decreased levels of HIV-1 antibodies after allo-
HSCT, which were maintained after 2 years of ATI 
(figure 4). Western blot analysis of antibodies showed a 
persistent loss of multiple bands since allo-HSCT until 
2 years after ATI, but with persistent presence of gp160 
and gp110/120 antibodies in all samples analysed 
(appendix p 9).
The absence of rebound after ART interruption could 
be due to two mechanisms: a reduction in the latent 
reservoir after conditioning and transplantation;11,12 and 
a reduction in the fraction of susceptible target cells for 
CCR5 tropic virus because of engraftment of donor 
CCR5Δ32/Δ32 cells.13,14 To understand the relative role of 
each mechanism alone and in combination, we used a 
mathematical model of latent and active HIV-1 dynamics. 
This model is based on previously developed tools to 
understand the effect of reservoir size on rebound time8–10 
and is adapted to account for the effect of a reduced target 
cell pool on viral growth (appendix pp 1–5). Although 
donor cell chimerism was measured in PBMCs to be 
approximately 99%, we postulated that this fraction could 
be lower in tissue sites vital for HIV-1 replication. 
Therefore, we considered a range of scenarios for the 
fraction of cells susceptible to HIV-1 infection. For each 
scenario, we simulated the distribution of expected 
rebound times and the probability of long-term remission 
(cure) as a function of reservoir size at the time of ART 
interruption (appendix p 3). These results were then used 
to calculate the probability that the patient would remain 
in remission for life, in view of observations of 29 months 
without rebound and no viral outgrowth seen in 24 million 
CD4 T cells, as previously reported at 18 months4 
(figure 5). If target cells remain susceptible to infection 
Figure 3: EBV-specific T-cell responses
Representative fluorescence-activated cell sorting plots showing percentage of 
virus-specific CD8 T cells (upper panel) and CD4 T cells (lower panel) identified 
via intracellular staining for IFNγ after stimulation with PepTivator EBV 
consensus pool at 1309 days after allo-HSCT (A). A negative control containing 
peripheral blood mononuclear cells from the London patient but without 
peptide mix was included (unstimulated) for each assay (A). Polyfunctional 
profile for CD8 and CD4 T-cell responses to EBV peptide pool stimulation 
subsequent to Boolean gating. The functions are listed along the x axis with 
each of their respective combinations (B). Allo-HSCT=allogeneic haemopoietic 
stem-cell transplantation. EBV=Epstein-Barr virus. IFNγ=interferon γ. 
IL2=interleukin 2. TNFα=tumour necrosis factor α.
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(and reservoir reduction is the main mechanism for 
delayed rebound), the model predicts there is only a 38% 
chance the patient will be in remission for life. With 50% 
chimerism, the likelihood of full remission jumps to 
87%; with 80% chimerism, the chance of remission rises 
to 98%. For 90% or higher reduction in susceptible cells, 
we estimate a negligible chance of future rebound.
Discussion
After extensive tissue sampling completed by 3·5 years 
after ATI, the Berlin patient was reported as being cured 
from HIV-1.3 The London patient has been in HIV 
remission for 30 months (as of March 4, 2020), with 
plasma negative for HIV-1 RNA (<1 copy per mL) and 
semen negative at less than 12 copies per mL at 
21 months. HIV-1 replication can occur in the CNS even 
during suppressive ART15 and is frequently associated 
with symptoms and MRI abnormalities.16 However, no 
detectable virus was recorded in CSF. Similarly, intestinal 
lymphoid tissue is an important HIV reservoir17 and 
HIV-1 DNA was negative in gut biopsy samples by 
ddPCR and rtPCR.
Similar to the Berlin patient,18 highly sensitive tests 
showed very low levels of so-called fossilised HIV-1 DNA in 
some tissue samples from the London patient. Residual 
HIV-1 DNA in axillary lymph node tissue could represent a 
defective clone that expanded during hyperplasia within 
the lymph node sampled. In support of this hypothesis, we 
recorded EBV-specific CD4 and CD8 responses in 
peripheral blood, although we were unable to separate 
lymph node-associated T cells for testing. Sequence 
analysis of HIV-1 DNA in lymph nodes was not successful, 
probably because of the very low copy number; therefore, 
we cannot fully rule out the possibility that very low levels 
of intact HIV-1 provirus have persisted. The signal could 
also be attributable to contamination, although sequencing 
would be needed to investigate this possibility further.
Myeloid cells (eg, macrophages) are also present in 
lymph nodes and are susceptible to both T-cell dependent 
and independent infection with HIV-1,19–22 and they 
survive chemotherapy with drugs such as etoposide.23,24 
Myeloid cells can also proliferate25 and could, therefore, 
have contributed to the noted HIV-1 DNA signal in 
lymph node tissue.
Moreover, a low-level signal in peripheral memory CD4 
T cells was recorded by ddPCR. Such occasional low-level 
positive signals were also seen in the Berlin patient18 and, 
previously, in CD4 T cells in the London patient,26 which 
could reflect a false ddPCR signal, potential contamination, 
or evidence of very low levels of persistent HIV-1 DNA-
positive cells.
HIV-1-specific CD4 and CD8 T-cell responses also 
remained below detection, by contrast with mainten-
ance of CMV-specific responses. We saw declining 
Figure 5: Estimated probability of long-term remission in the London 
patient
Probability of long-term remission (cure) is calculated as a function of the 
observed time off ART without rebound and the fraction of target cells that are 
protected from infection. Calculations were based on a stochastic mathematical 
model of reservoir dynamics and rebound. The dotted horizontal line shows the 
current time off ART of 29 months. Long-term remission was defined as 70 years 
without rebound. ART=antiretroviral therapy.































Figure 4: HIV-specific antibodies
Humoral response dynamics were tested up to 1316 days after allo-HSCT. 
Antibody levels were measured using the standard HIV-1 Vitros assay (A), 
a detuned low-sensitive version of the HIV-1 Vitros assay (B), and the limiting 
antigen avidity assay (C). White circles represent values under the LOD. Grey 
shading denotes the period off cART. Allo-HSCT=allogeneic haemopoietic 
stem-cell transplantation. cART=combined antiretroviral therapy. LOD=limit 
of detection.
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responses in HIV-1 specific antibodies up to 27 months 
after ATI using detuned (low-sensitive) and low-avidity 
assays, despite positive ELISA. Western blot results 
showed similar appearances at 27 months compared 
with at 18 months after ATI, with only gp160 antibodies 
remaining. These results are consistent with a positive 
standard ELISA against HIV-1 env reported previously 
both in the London patient and the Berlin patient.1,4 
We believe that persistent HIV-1 Env-specific plasma 
cells could have survived allo-HSCT27 and that the low-
level env PCR signal in lymph nodes could be related to 
this observation. Standard ELISA testing, therefore, 
cannot be used as a marker for cure, although more 
work needs to be done to assess the role of detuned and 
low-avidity antibody assays in defining cure.
The slow recovery in CD4 count in the London patient 
could be the result of the lengthy duration of untreated 
HIV infection between 2003 and 2013 or to the effects of 
alemtuzumab (anti-CD52 monoclonal antibody used for 
lymphodepletion in the setting of allo-HSCT). The noted 
reactivation of EBV at 21 months after ATI could have 
been related to this continued relative immuno suppres-
sion, although CMV reactivation did not occur at that 
time and no opportunistic infections arose. Importantly, 
the London patient did not receive any cytotoxic agents or 
GvHD prophylaxis beyond 6 months after allo-HSCT.4
Mathematical modelling suggested that if more than 
80% of target cells were donor-derived then remission for 
life (cure) was 98% likely in view of no rebound at 
29 months. With chimerism higher than 90%, cure is 
almost certain in the model. These results can be 
understood along the same principle as the vaccination 
threshold in epidemiology.28 As long as a critical fraction 
of target cells are protected (eg, a critical percentage of 
chimerism is reached), the infection cannot grow 
exponentially. This critical fraction depends on the value 
of the basic reproduction ratio (R0) for the infection, and 
a distribution for this value across patients can be 
estimated from viral growth rates during acute infection 
combined with estimates of the HIV generation time 
(appen dix pp 1–5). We plan to do viral load testing twice a 
year up to 60 months after ATI before testing yearly to 
120 months.
In conclusion, we believe these findings probably 
represent the second recorded HIV-1 cure after 
CCR5Δ32/Δ32 allo-HSCT, with evidence of residual low-
level HIV-1 DNA. Despite showing (in both the London 
patient and the Berlin patient) that CCR5-directed 
approaches can lead to long-term remission of HIV-1, 
several barriers remain to be overcome (eg, gene editing 
efficiency and robust safety data) before CCR5 gene 
editing can be used as a scalable cure strategy for 
HIV-1.29–31
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